We believe Cochrane is a key source of scientific evidence on diagnostic and therapeutic medical issues. The very recent expulsion of Peter Gøtzsche from the Cochrane Board and subsequent retirement of four Board members have great impact on the existence of this organisation. Beside issues mentioned by other authors1-3 we believe this crisis is a good opportunity to fix a big problem raised by Peter Gøtzsche and others about Cochrane’s conflict of interest policy.
Paris, 28 November 2017
Prescrire, along with around 20 civil society organisations, has signed a joint declaration drawing attention to potential problems posed by the provision of confidential scientific advice by the European Medicines Agency to pharmaceutical companies, especially a decline in regulatory standards, a risk of institutional capture, and a total lack of transparency surrounding the activity of European regulatory authorities.
Brussels, 8 September 2017
33 civil society organisations, including Prescrire, acting together in the name of responsible pharmaceutial research and affordable medicines, called for the European Commission to abolish the mechanism of supplementary protection certificates (SPCs).
Brussels, 18 May 2017
In a joint response to the EMA's consultation on its policy on access to documents, Health Action International, the International Society of Drug Bulletins, NoGracias, the Nordic Cochrane Centre and Prescrire called for a comprehensive public register of all the documents the EMA produces and receives. The coalition also strongly encourages the EMA to increase resources so it can more efficiently handle access requests to documents.
Paris, 13 January 2017
In a joint response to the EU Commission Consultation on health technology assessment, Prescrire, the International Socety of Drug Bulletins and the Medicines in Europe Forum argue in favour of transparency, independence and high-quality evidentiary standards.